Significant differential effects of omega-3 fatty acids and fenofibrate in patients with hypertriglyceridemia
- Authors
- Koh, Kwang Kon; Quon, Michael J.; Shin, Kwen-Chul; Lim, Soo; Lee, Yonghee; Sakuma, Ichiro; Lee, Kyounghoon; Han, Seung Hwan; Shin, Eak Kyun
- Issue Date
- Feb-2012
- Publisher
- ELSEVIER IRELAND LTD
- Keywords
- Omega-3 fatty acids; Fenofibrate; Insulin resistance; Hypertriglyceridemia
- Citation
- ATHEROSCLEROSIS, v.220, no.2, pp.537 - 544
- Journal Title
- ATHEROSCLEROSIS
- Volume
- 220
- Number
- 2
- Start Page
- 537
- End Page
- 544
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/16598
- DOI
- 10.1016/j.atherosclerosis.2011.11.018
- ISSN
- 0021-9150
- Abstract
- Background: Omega-3 fatty acids and fenofibrate are both used to treat patients with hypertriglyceridemia. However, a head-to-head comparison of the lipoprotein and metabolic effects of these two medicines has not been published. Methods: This was a randomized, single-blind, placebo-controlled, parallel study. Age, sex, and body mass index were matched among groups. All patients were recommended to maintain a low fat diet. Fifty patients in each group were given placebo, omega-3 fatty acids 2 g (most commonly used dosage in Korean patients), or fenofibrate 160 mg, respectively daily for 2 months. Results: Omega-3 fatty acids therapy decreased triglycerides by 21% and triglycerides/HDL cholesterol and improved flow-mediated dilation (P < 0.01), however, did not significantly change insulin, plasma adiponectin levels, and insulin sensitivity (determined by QUICKI) relative to baseline measurements. Fenofibrate therapy decreased total cholesterol, triglycerides by 29%, and triglycerides/HDL-cholesterol (all P < 0.01) and improved flow-mediated dilation when compared with baseline. When compared with placebo and omega-3 fatty acids, fenofibrate therapy decreased non-HDL cholesterol (P < 0.001) and triglycerides/HDL cholesterol (P = 0.016) while increasing HDL cholesterol (P < 0.001) and apolipoprotein AI (P = 0.001). Of note, when compared with omega-3 fatty acids, fenofibrate therapy decreased fasting insulin (P = 0.023) and increased plasma adiponectin (P = 0.002) and insulin sensitivity (P = 0.015). Conclusions: Omega-3 fatty acids and fenofibrate therapy promoted similar changes in triglycerides and endothelium-dependent dilation. However, fenofibrate therapy had substantially better effects on lipoprotein and metabolic profiles in patients with hypertriglyceridemia. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/16598)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.